DK1971362T3 - Exendin til behandling af diabetes og reduktion af legemsvægt - Google Patents

Exendin til behandling af diabetes og reduktion af legemsvægt Download PDF

Info

Publication number
DK1971362T3
DK1971362T3 DK06801867.0T DK06801867T DK1971362T3 DK 1971362 T3 DK1971362 T3 DK 1971362T3 DK 06801867 T DK06801867 T DK 06801867T DK 1971362 T3 DK1971362 T3 DK 1971362T3
Authority
DK
Denmark
Prior art keywords
exendin
gly
ala
glu
ser
Prior art date
Application number
DK06801867.0T
Other languages
English (en)
Inventor
Mark Fineman
Leigh Macconell
Kristin Taylor
Original Assignee
Amylin Pharmaceuticals Llc
Astrazeneca Pharmaceuticals Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37772212&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1971362(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amylin Pharmaceuticals Llc, Astrazeneca Pharmaceuticals Lp filed Critical Amylin Pharmaceuticals Llc
Application granted granted Critical
Publication of DK1971362T3 publication Critical patent/DK1971362T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates

Claims (13)

1. Formulering omfattende en agonist tii exendin, eiier ti! en exendin-anaiog, en biokompatibei polymer, og en sukker ti! anvendelse i en fremgangsmåde til behandling af diabetes i et menneske, hvor nævnte fremgangsmåde omfatter: (a) indgivelse af formuleringen tii mennesket en gang ugentligt; og (b) indgivelse af tilstrækkelig formulering tii at opretholde en vedvarende plasmakoncentration af agonisten tii exendin, eiier ti! en exendin-anaiog, på fra ca. 170 pg / ml ti! ca. 600 pg / ml i mindst 1 måned.
2. En formulering til anvendelse ifølge krav 1, hvor mennesket er overvægtigt, eller ønsker, eller har behov for, at reducere sin legemsvægt.
3. En formulering til anvendelse ifølge krav 1 eller krav 2, hvor den vedvarende plasma-koncentration af agonisten tii exendin, eller til en exendin-anaiog, er fra ca. 170 pg / ml til ca. 350 pg / ml.
4. En formulering fil anvendelse ifølge et hvilket som helst af kravene 1 til 3, hvor agonisten ti! exendin, eller til en exendin-anaiog, er exendin-4.
5. En formulering til anvendelse ifølge et hvilket som helst af kravene 1 ti! 4, hvor sukkeret er saccharose.
6. En formulering til anvendelse ifølge et hvilket som helst af kravene 1 til 5, hvor formuleringen indgives én gang om ugen ved subkutan injektion.
7. En formulering ti! anvendelse ifølge et hvilket som helst af kravene 1 til 6, hvor den pågældende diabetes er type Π diabetes.
8. Anvendelse af en agonist til exendin, eller til en exendin-analog, til fremstilling af et lægemiddel omfattende en agonist til en exendin-analog, en biokompatibel polymer, og en sukker til anvendelse i en fremgangsmåde ti! behandling af diabetes i et menneske, hvor nævnte fremgangsmåde omfatter: (a) administration af lægemidlet ti! mennesket en gang ugentligt; og (b) administration af tilstrækkeligt lægemiddel til at opretholde en vedvarende plasma-koncentration afen agonist ti! exendin, eiier til en exendin-anaiog, på fra ca. 170 pg / mi til ca. 600 pg / ml i mindst 1 måned.
9. Anvendelse ifølge krav 8, hvor mennesket er overvægtigt, eller ønsker, eller har behov for, at reducere sin legemsvægt.
10. Anvendelse ifølge krav 8 eller krav 9, hvor den vedvarende plasmakoncentration af agonisten til exendin, eller ti! en exendin-analog, er fra ca. 170 pg / ml til ca. 350 pg / ml.
11. Anvendelse ifølge et hvilket som helst af kravene 8 til 10, hvor agonisten til exendin, eller ti! en exendin-analog, er exendin-4.
12. Anvendelse ifølge et hvilket som helst af kravene 8 ti! 11, hvor lægemidlet indgives én gang ugentligt ved subkutan injektion.
13. Anvendelse ifølge et hvilket som helst af kravene 8 til 12, hvor den pågældende diabetes er type il diabetes.
DK06801867.0T 2005-08-19 2006-08-18 Exendin til behandling af diabetes og reduktion af legemsvægt DK1971362T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70960405P 2005-08-19 2005-08-19
US77921606P 2006-03-03 2006-03-03
PCT/US2006/032354 WO2007024700A2 (en) 2005-08-19 2006-08-18 Exendin for treating diabetes and reducing body weight

Publications (1)

Publication Number Publication Date
DK1971362T3 true DK1971362T3 (da) 2015-01-26

Family

ID=37772212

Family Applications (3)

Application Number Title Priority Date Filing Date
DK19163698.4T DK3524261T3 (da) 2005-08-19 2006-08-18 Exendin til anvendelse til behandling af diabetes og reduktion af kropsvægt
DK06801867.0T DK1971362T3 (da) 2005-08-19 2006-08-18 Exendin til behandling af diabetes og reduktion af legemsvægt
DK10016112.4T DK2347762T3 (da) 2005-08-19 2006-08-18 Exendin til behandling af diabetes og reduktion af kropsvægt

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK19163698.4T DK3524261T3 (da) 2005-08-19 2006-08-18 Exendin til anvendelse til behandling af diabetes og reduktion af kropsvægt

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK10016112.4T DK2347762T3 (da) 2005-08-19 2006-08-18 Exendin til behandling af diabetes og reduktion af kropsvægt

Country Status (25)

Country Link
US (7) US20090239796A1 (da)
EP (3) EP1971362B1 (da)
JP (2) JP5693817B2 (da)
KR (1) KR101059279B1 (da)
CN (1) CN105056211A (da)
AU (2) AU2006283517B2 (da)
BR (1) BRPI0615358B8 (da)
CA (1) CA2619426C (da)
CY (1) CY1122010T1 (da)
DK (3) DK3524261T3 (da)
ES (2) ES2736184T3 (da)
FI (1) FI3524261T3 (da)
HR (1) HRP20150186T1 (da)
HU (1) HUE045165T2 (da)
IL (2) IL189607A (da)
LT (1) LT2347762T (da)
MX (1) MX2008002370A (da)
NZ (2) NZ566763A (da)
PL (2) PL1971362T3 (da)
PT (3) PT3524261T (da)
RS (1) RS53814B1 (da)
RU (1) RU2421237C2 (da)
SG (1) SG184730A1 (da)
SI (3) SI1971362T1 (da)
WO (1) WO2007024700A2 (da)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
ATE388698T1 (de) 2003-04-29 2008-03-15 Orexigen Therapeutics Inc Zusammensetzungen zur beeinflussung des gewichtsverlusts
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
ES2736184T3 (es) 2005-08-19 2019-12-26 Amylin Pharmaceuticals Llc Exendina para el tratamiento de la diabetes y la reducción del peso corporal
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
CN102274557B (zh) 2006-08-09 2014-12-03 精达制药公司 渗透性递送系统和活塞组件
NZ580447A (en) 2007-04-23 2011-06-30 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and uses thereof
JP2009019027A (ja) * 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US20110263496A1 (en) 2008-05-21 2011-10-27 Amylin Pharmaceuticals, Inc. Exendins to lower cholesterol and triglycerides
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
EA020299B1 (ru) 2008-09-04 2014-10-30 АМИЛИН ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Составы с замедленным высвобождением, полученные с применением неводных носителей
WO2010043566A2 (de) 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Kombination von einem insulin und einem glp-1-agonisten
WO2010138671A1 (en) 2009-05-28 2010-12-02 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonist compounds for sleep enhancement
EP3466438A1 (en) 2009-08-03 2019-04-10 Incube Labs, Llc Swallowable capsule and method for stimulating incretin production within the intestinal tract
CA2775676C (en) 2009-09-28 2016-08-16 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
EP2496249B1 (en) 2009-11-03 2016-03-09 Amylin Pharmaceuticals, LLC Glp-1 receptor agonist for use in treating obstructive sleep apnea
AU2010317994B2 (en) 2009-11-13 2014-03-06 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
PL2498802T3 (pl) 2009-11-13 2015-06-30 Sanofi Aventis Deutschland Kompozycja farmaceutyczna zawierająca agonistę GLP-1, insulinę i metioninę
US8759284B2 (en) 2009-12-24 2014-06-24 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
WO2011085331A1 (en) 2010-01-11 2011-07-14 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression
EP2389945A1 (en) * 2010-05-28 2011-11-30 Sanofi-Aventis Deutschland GmbH Pharmaceutical composition comprising AVE0010 and insulin glargine
AU2010360116B2 (en) 2010-08-30 2014-06-26 Sanofi-Aventis Deutschland Gmbh Use of AVE0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
WO2012054817A1 (en) * 2010-10-22 2012-04-26 Mitokine Bioscience, Llc Delaying and/ or treating hyperglycemia, including diabetes, with poly(alkyl carboxylic acids)
MX345501B (es) 2010-12-16 2017-02-02 Novo Nordisk As Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
US9283179B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9284367B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8846040B2 (en) 2010-12-23 2014-09-30 Rani Therapeutics, Llc Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8809271B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising liraglutide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9629799B2 (en) 2010-12-23 2017-04-25 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9259386B2 (en) 2010-12-23 2016-02-16 Rani Therapeutics, Llc Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10639272B2 (en) 2010-12-23 2020-05-05 Rani Therapeutics, Llc Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US8980822B2 (en) 2010-12-23 2015-03-17 Rani Therapeutics, Llc Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402806B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9861683B2 (en) 2010-12-23 2018-01-09 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8734429B2 (en) 2010-12-23 2014-05-27 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9415004B2 (en) 2010-12-23 2016-08-16 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402807B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8809269B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9050347B2 (en) 2011-01-25 2015-06-09 Viviabiotech, S.L. 1,2,4-oxadiazole derivatives as drugs modulating the GLP-1 peptide receptor
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN106117343B (zh) 2011-04-12 2020-11-03 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9944687B2 (en) 2011-07-04 2018-04-17 Imperial Innovations Limited Compounds and their effects on feeding behaviour
WO2013030160A1 (en) 2011-08-29 2013-03-07 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
US10865419B2 (en) * 2011-10-24 2020-12-15 The Trustees Of The University Of Pennsylvania Orally administered plastid expressed cholera toxin B subunit-exendin 4 as treatment for type 2 diabetes
US10933120B2 (en) 2012-03-22 2021-03-02 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
HUE042757T2 (hu) 2012-03-22 2019-07-29 Novo Nordisk As Szállító szert tartalmazó készítmények és elõállításuk
KR20210012056A (ko) 2012-06-06 2021-02-02 오렉시젠 세러퓨틱스 인크. 과체중 및 비만의 치료 방법
CN104487056A (zh) 2012-06-20 2015-04-01 诺和诺德A/S（股份有限公司） 包含肽和递送剂的片剂制剂
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
RU2015129788A (ru) 2012-12-21 2017-01-30 Санофи Производные эксендина-4 как двойные агонисты glp1/gip или тройные агонисты glp1/gip/глюкагона
US20160039877A1 (en) 2013-03-15 2016-02-11 Shenzhen Hightide Biopharmaceutical, Ltd. Compositions and methods of using islet neogenesis peptides and analogs thereof
LT2991671T (lt) 2013-05-02 2018-09-25 Novo Nordisk A/S Geriami glp-1 junginiai
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
WO2015169789A1 (en) * 2014-05-07 2015-11-12 Novo Nordisk A/S Treatment of diabetes type 1 using glp-1 and anti-il-21
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
RU2573933C1 (ru) * 2014-08-21 2016-01-27 Дафот Энтерпрайсис Лимитед Пептид для лечения сахарного диабета 2-го типа и его осложнений
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2016070117A1 (en) * 2014-11-02 2016-05-06 Nano Precision Medical, Inc. Implantable medical devices for extended release of therapeutic agents
HUE062573T2 (hu) 2014-12-12 2023-11-28 Sanofi Aventis Deutschland Glargin inzulin/lixiszenatid rögzített arányú készítmény
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CN107613986A (zh) * 2015-04-07 2018-01-19 英特塞普特医药品公司 用于组合疗法的药物组合物
HRP20211768T1 (hr) 2015-05-22 2022-02-18 The Board Of Trustees Of The Leland Stanford Junior University Liječenje postbarijatrijske hipoglikemije s antagonistima glp-1
KR101661332B1 (ko) * 2015-05-28 2016-09-29 (의료)길의료재단 글루카곤 유사 펩타이드-1 수용체 항진제를 포함하는 근감소증 치료용 약학 조성물
CN113598842A (zh) 2015-06-03 2021-11-05 因塔西亚制药公司 植入物放置和移除系统
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
US20170098040A1 (en) * 2015-10-06 2017-04-06 Scale Down Weight management system and method
WO2017152014A1 (en) 2016-03-04 2017-09-08 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
EP3468576B1 (en) 2016-04-15 2023-06-07 Syracuse University Peptide drug improvement using vitamin b12 and haptocorrin binding substrate conjugates
EP3458084B1 (en) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
EP3515408A1 (en) 2016-09-23 2019-07-31 Delpor, Inc. Stable compositions for incretin mimetic compounds
CN110267648A (zh) 2016-11-21 2019-09-20 艾格尔峰生物制药有限公司 毒蜥外泌肽(9-39)的缓冲制剂
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
DK3570874T3 (da) * 2017-01-17 2023-04-11 Univ Wayne State Zwitterionisk polymer-insulin-sammensætninger og dertil relaterede fremgangsmåder
US20200188479A1 (en) 2017-03-08 2020-06-18 Intarcia Therapeutics, Inc. Apparatus and methods for administration of a nauseogenic compound from a drug delivery device
WO2018191599A1 (en) * 2017-04-14 2018-10-18 University Of Massachusetts Brown fat-selective adipokines
BR112019023511A2 (pt) 2017-05-11 2020-05-19 Shenzhen Hightide Biopharmaceutical Ltd uso de compostos peptídeos no tratamento de pancreatite aguda
BR112020014624A2 (pt) 2018-02-02 2020-12-08 Novo Nordisk A/S Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante
WO2019240755A1 (en) * 2018-06-11 2019-12-19 Wellesley Pharmaceuticals, Llc Pharmaceutical compositions and methods for weight loss
KR20210077693A (ko) * 2018-10-12 2021-06-25 미라키 이노베이션 씽크 탱크 엘엘씨 지방 감소용 냉각 용액
EP3875476A4 (en) * 2018-10-30 2022-08-24 Jianning Liu GLP-1 POLYPEPTIDE WITH GLP-1 RECEPTOR AGONIST ACTIVITY AND USES THEREOF
WO2021214023A1 (en) 2020-04-22 2021-10-28 Bayer Aktiengesellschaft Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases
KR102556528B1 (ko) * 2020-12-08 2023-07-17 경희대학교 산학협력단 대사성 질환 예방, 개선 또는 치료용 조성물

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US386998A (en) 1888-07-31 Boiler
US3490597A (en) 1966-07-22 1970-01-20 Purolator Products Inc Cover plate for spin-on-filter
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5445781A (en) 1991-08-28 1995-08-29 Centro Sviluppo Settori Impiego S.R.L. Process for the injection molding of non-precatalyzed polymerizable resins at high-pressure and flow
US5509305A (en) 1992-02-12 1996-04-23 Daniel Industries, Inc. Closely coupled, dual turbine volumetric flow meter
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
GB2282891B (en) 1993-10-13 1997-09-03 Tokai Rika Co Ltd Acceleration detecting apparatus
CA2474701C (en) 1993-11-19 2009-01-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradeable microparticles containing a biologically active agent
US5650173A (en) 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
ATE417622T1 (de) 1996-08-08 2009-01-15 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
DK0996459T3 (da) 1997-01-07 2006-01-16 Amylin Pharmaceuticals Inc Anvendelse af exendiner og agonister deraf til reduktion af födeindtagelse
EP1512395A1 (en) 1997-07-18 2005-03-09 Azopax Therapeutics LLC Biodegradable macromers for the controlled release of biologically active substances
DK1143989T3 (da) 1999-01-14 2007-04-16 Amylin Pharmaceuticals Inc Exendiner til glucagonundertrykkelse
EP1140145B2 (en) 1999-01-14 2019-05-15 Amylin Pharmaceuticals, LLC Novel exendin agonist formulations and methods of administration thereof
US20030087820A1 (en) 1999-01-14 2003-05-08 Young Andrew A. Novel exendin agonist formulations and methods of administration thereof
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
EP1175443A1 (en) * 1999-04-30 2002-01-30 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6162260A (en) 1999-05-24 2000-12-19 Novo Nordisk Biochem North America, Inc. Single-bath biopreparation and dyeing of textiles
ES2227115T5 (es) 2000-01-10 2014-10-30 Amylin Pharmaceuticals, Inc. Utilización de exendinas y sus agonistas para el tratamiento de la hipertrigliceridemia
US6602997B2 (en) 2000-04-27 2003-08-05 Shin-Etsu Bio, Inc. Whole cell and cell-debris polysaccharide
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6479065B2 (en) 2000-08-10 2002-11-12 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US7259233B2 (en) 2000-12-13 2007-08-21 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
US6819912B2 (en) 2001-11-05 2004-11-16 Freescale Semiconductor, Inc. Variable frequency switching amplifier and method therefor
US7092459B2 (en) 2001-11-08 2006-08-15 Qualcomm, Incorporated Frequency tracking using pilot and non-pilot symbols
GB0206792D0 (en) 2002-03-22 2002-05-01 Leuven K U Res & Dev Normoglycemia
US20040121009A1 (en) * 2002-10-17 2004-06-24 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
WO2004035762A2 (en) 2002-10-17 2004-04-29 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
US7790681B2 (en) 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
WO2005040195A2 (en) 2003-10-24 2005-05-06 Azopax Therapeutics Llc Formulation of exendins
WO2005041873A2 (en) 2003-10-24 2005-05-12 Azopax Therapeutics Llc Formulation of exendin-4
TWI353250B (en) 2003-12-16 2011-12-01 Ipsen Pharma Sas Glp-1 pharmaceutical compositions
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
PL1734971T3 (pl) * 2004-04-15 2012-08-31 Alkermes Pharma Ireland Ltd Urządzenie o przedłużonym uwalnianiu na bazie polimeru
NZ551196A (en) 2004-05-14 2010-08-27 Emisphere Tech Inc Compounds and compositions for delivering active agents
PL1765310T3 (pl) 2004-05-28 2016-04-29 Oryxe Mieszanina do podawania przezskórnego nisko- i wysokocząsteczkowych związków
PT1786400E (pt) 2004-08-12 2009-06-19 Quest Pharmaceutical Services Composições farmacêuticas para a libertação controlada de compostos biologicamente activos
US20060034889A1 (en) 2004-08-16 2006-02-16 Macromed, Inc. Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof
US7442682B2 (en) 2004-10-19 2008-10-28 Nitto Denko Corporation Transepithelial delivery of peptides with incretin hormone activities
WO2007022518A2 (en) 2005-08-19 2007-02-22 Amylin Pharmaceuticals, Inc. New uses of glucoregulatory proteins
ES2736184T3 (es) 2005-08-19 2019-12-26 Amylin Pharmaceuticals Llc Exendina para el tratamiento de la diabetes y la reducción del peso corporal
US7512298B2 (en) 2006-12-01 2009-03-31 3M Innovative Properties Company Optical sensing methods
IT1402944B1 (it) 2010-12-15 2013-09-27 Sarong Spa Capsula per bevande e relativa macchina per utilizzare detta capsula
US11638099B2 (en) 2011-12-23 2023-04-25 Shenzhen Shokz Co., Ltd. Bone conduction speaker and compound vibration device thereof
JP6226510B2 (ja) 2012-01-27 2017-11-08 キヤノン株式会社 画像処理システム、処理方法及びプログラム
ITMI20130325A1 (it) 2013-03-05 2014-09-06 Telecom Italia Spa Metodo per misurare e monitorare il livello di accesso a dati personali generati da risorse di un dispositivo d'utente
US9816387B2 (en) 2014-09-09 2017-11-14 United Technologies Corporation Attachment faces for clamped turbine stator of a gas turbine engine
CA2914090C (en) 2015-03-31 2023-08-01 Allen-Vanguard Corporation Frequency and time domain streaming receiver
US9714199B2 (en) 2015-09-17 2017-07-25 I P Creations Limited Concealed amalgamated explosive neutralizer and method of manufacture

Also Published As

Publication number Publication date
JP5693817B2 (ja) 2015-04-01
JP2015044831A (ja) 2015-03-12
US8906851B2 (en) 2014-12-09
IL189607A (en) 2016-10-31
IL243317A0 (en) 2016-02-29
WO2007024700A3 (en) 2007-08-09
DK3524261T3 (da) 2024-01-15
ES2736184T3 (es) 2019-12-26
HUE045165T2 (hu) 2019-12-30
US20200222509A1 (en) 2020-07-16
US20130172243A1 (en) 2013-07-04
BRPI0615358B8 (pt) 2021-05-25
PL1971362T3 (pl) 2015-05-29
RS53814B1 (en) 2015-06-30
IL189607A0 (en) 2008-06-05
EP1971362B1 (en) 2014-12-03
SI1971362T1 (sl) 2015-03-31
US20160271225A1 (en) 2016-09-22
EP2347762A1 (en) 2011-07-27
AU2006283517B2 (en) 2010-12-02
US20150150948A1 (en) 2015-06-04
US9884092B2 (en) 2018-02-06
US20090239796A1 (en) 2009-09-24
ES2526463T3 (es) 2015-01-12
AU2011200663B2 (en) 2013-02-28
JP5980872B2 (ja) 2016-08-31
RU2421237C2 (ru) 2011-06-20
PT1971362E (pt) 2015-02-10
NZ593461A (en) 2013-01-25
SG184730A1 (en) 2012-10-30
NZ566763A (en) 2011-06-30
EP3524261A1 (en) 2019-08-14
KR101059279B1 (ko) 2011-08-24
SI2347762T1 (sl) 2019-09-30
WO2007024700A8 (en) 2007-12-27
RU2008110504A (ru) 2009-09-27
JP2009504775A (ja) 2009-02-05
SI3524261T1 (sl) 2024-02-29
LT2347762T (lt) 2019-08-26
BRPI0615358B1 (pt) 2019-03-26
FI3524261T3 (fi) 2024-01-11
US20180333468A1 (en) 2018-11-22
CY1122010T1 (el) 2020-10-14
HRP20150186T1 (hr) 2015-05-22
PT3524261T (pt) 2024-01-12
CA2619426C (en) 2016-06-21
EP3524261B1 (en) 2023-12-13
WO2007024700A2 (en) 2007-03-01
EP1971362A2 (en) 2008-09-24
MX2008002370A (es) 2008-04-29
EP2347762B1 (en) 2019-05-08
AU2006283517A1 (en) 2007-03-01
AU2011200663A1 (en) 2011-03-10
BRPI0615358A2 (pt) 2011-05-17
CA2619426A1 (en) 2007-03-01
PL2347762T3 (pl) 2019-09-30
PT2347762T (pt) 2019-06-17
US20110245162A1 (en) 2011-10-06
DK2347762T3 (da) 2019-06-11
KR20080038411A (ko) 2008-05-06
US8329648B2 (en) 2012-12-11
CN105056211A (zh) 2015-11-18

Similar Documents

Publication Publication Date Title
US20200222509A1 (en) Methods for treating diabetes and reducing body weight
US8299024B2 (en) Methods to restore glycemic control
AU2003239910B2 (en) Novel exendin agonist formulations and methods of administration thereof
WO2009143285A2 (en) Exendins to lower cholestrol and triglycerides
AU2013205769A1 (en) Exendin for treating diabetes and reducing body weight